Advanced search
Publication Cover
Future Oncology Volume 15, 2019 - Issue 33
Submit an article Journal homepage
844
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Clinical Utility Versus Futility: A Tipping Point for Liquid Biopsies in Bladder Cancer

Erik Kouba1 Associated Pathologists at Medical Center of Central Georgia, Macon, GA 46202, USA
&
Liang Cheng2 Department of Pathology&Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA;3 Department of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6049-5293
ORCID Icon
Pages 3751-3753 | Received 28 Aug 2019, Accepted 09 Sep 2019, Published online: 25 Oct 2019

References

  • Cheng L , EbleJN. Molecular Surgical Pathology. Springer, NY, USA (2013).
  • Cheng L , ZhangDY, EbleJN. Molecular Genetic Pathology. Springer, NY, USA (2013).
  • Bardelli A , PantelK. Liquid biopsies, what we do not know (yet). Cancer Cell31, 172–179 (2017).
  • Saarenheimo J , EigelieneN, AndersenHet al. The value of liquid biopsies for guiding therapy decisions in non-small cell lung cancer. Front. Oncol.9, 129 (2019).
  • Riethdorf S , SoaveA, RinkM. The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer. Transl. Androl. Urol.6, 1090–1110 (2017).
  • Otandault A , AnkerP, AlAmir Dache Zet al. Recent advances in circulating nucleic acids in oncology. Ann. Oncol.30, 374–384 (2019).
  • Pantel K , Alix-PanabieresC. Liquid biopsy and minimal residual disease – latest advances and implications for cure. Nat. Rev. Clin. Oncol.16, 409–424 (2019).
  • Cheng L , Lopez-BeltranA, BostwickDG. Bladder Pathology. Wiley-Blackwell, NJ, USA (2012).
  • Cheng L , MacLennanGT, BostwickDG. Urologic Surgical Pathology. Elsevier, PA, USA (2019).
  • Cheng L , ZhangS, MacLennanGTet al. Bladder cancer: translating molecular genetic insights into clinical practice. Hum. Pathol.42, 455–481 (2011).
  • Rossi G , IgnatiadisM. Promises and pitfalls of using liquid biopsy for precision medicine. Cancer Res.79, 2798–2804 (2019).
  • Adams KT . Gene-based diagnostics: ready for prime time?Biotechnol. Healthc.2, 20–28 (2005).
  • Goossens N , NakagawaS, SunX, HoshidaY. Cancer biomarker discovery and validation. Transl. Cancer Res.4, 256–269 (2015).
  • Vandekerkhove G , TodenhoferT, AnnalaMet al. Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer. Clin. Cancer Res.23, 6487–6497 (2017).
  • Agarwal N , PalSK, HahnAWet al. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer124, 2115–2124 (2018).
  • Christensen E , Birkenkamp-DemtroderK, NordentoftIet al. Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer. Eur. Urol.71, 961–969 (2017).
  • Birkenkamp-Demtroder K , ChristensenE, NordentoftIet al. Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. Eur. Urol.73, 535–540 (2018).
  • Todenhofer T , StrussWJ, SeilerRet al. Liquid biopsy-analysis of circulating tumor DNA (ctDNA) in bladder cancer. Bladder Cancer4, 19–29 (2018).
  • Christensen E , Birkenkamp-DemtroderK, SethiHet al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clin. Oncol.37, 1547–1557 (2019).
  • Bronkhorst AJ , UngererV, HoldenriederS. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol. Detect. Quantif.17, 100087 (2019).
  • Abbosh C , BirkbakNJ, SwantonC. Early stage NSCLC – challenges to implementing ctDNA-based screening and MRD detection. Nat. Rev. Clin. Oncol.15, 577–586 (2018).
  • Reinert T , HenriksenTV, ChristensenEet al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. (2019) ( in press).
  • Buono G , GerratanaL, BulfoniMet al. Circulating tumor DNA analysis in breast cancer: is it ready for prime-time?Cancer Treat. Rev.73, 73–83 (2019).
  • Dudley JC , Schroers-MartinJ, LazzareschiDVet al. Detection and surveillance of bladder cancer using urine tumor DNA. Cancer Discov.9, 500–509 (2019).
  • Kaiser J . ‘Liquid biopsy’ for cancer promises early detection. Science359, 259 (2018).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.